Olanzapine (CED0001774)

Record Information

Version

1.0

Creation Date

2009-07-21 20:26:38 UTC

Update Date

2026-05-14 16:35:46 UTC

SynCED ID

CED0001774

Secondary Accession Numbers

CHEM002173
T3D2754

Identification

Common Name

Olanzapine

Class

Small Molecule

Description

Olanzapine belongs to the benzodiazepines, a class of organoheterocyclic compounds within the organic compounds. This exogenous solid has the chemical formula C17H20N4S and an average molecular weight of 312.43 g/mol. It is detected in the brain and liver tissues. Recorded exposure routes for the compound include oral, intramuscular, and inhalation. It has been found in antennas, indoor air, and antipsychotic pharmaceuticals and veterinary products. Olanzapine is used as a second generation antipsychotic and an antiemetic. Biologically, it functions as a serotonin uptake inhibitor and an antagonist for histamine, muscarinic, serotonergic, and dopaminergic receptors. It acts as an antagonist at types 1, 2, and 4 dopamine receptors, alpha(1)-receptors, histamine H1-receptors, muscarinic receptors 1 through 5, and 5-HT receptor types 2A and 2C. Its antipsychotic effect is attributed to antagonism at serotonin type 2 and dopamine receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors, which may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular trac. The compound interacts with 42 recorded protein targets, including the D(1A) dopamine receptor (DRD1), the Muscarinic acetylcholine receptors M1 (CHRM1), M3 (CHRM3), and M5 (CHRM5), as well as acting as an inhibitor of 5-hydroxytryptamine receptors 1A (HTR1A), 1B (HTR1B), 1D (HTR1D), and 1E (HTR1E).

Contaminant Type

Amine
Antiemetic
Antipsychotic Agent
Drug
Food Toxin
Human Neurotoxin
Metabolite
Organic Compound
Serotonin Uptake Inhibitor
Synthetic Compound

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
Olanzapina	ChEBI
Olanzapinum	ChEBI
Zyprexa	ChEBI
Lanzac	HMDB
Zyprexa intramuscular	HMDB
Zyprexa zydis	HMDB
Zolafren	HMDB
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine	HMDB
Olanzapine pamoate	HMDB

Chemical Formula

C₁₇H₂₀N₄S

Average Molecular Mass

312.432 g/mol

Monoisotopic Mass

312.141 g/mol

CAS Registry Number

132539-06-1

IUPAC Name

5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene

Traditional Name

zyprexa

SMILES

CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2

InChI Identifier

InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI Key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzodiazepines

Sub Class

Not Available

Direct Parent

Benzodiazepines

Alternative Parents

Substituents

Benzodiazepine
Thieno-para-diazepine
2,3,5-trisubstituted thiophene
Para-diazepine
N-methylpiperazine
N-alkylpiperazine
N-arylated-2-aminothiophene
1,4-diazinane
Piperazine
2-aminothiophene
Benzenoid
Imidolactam
Heteroaromatic compound
Thiophene
Tertiary aliphatic amine
Tertiary amine
Azacycle
Secondary amine
Amidine
Carboxylic acid amidine
Propargyl-type 1,3-dipolar organic compound
Organic 1,3-dipolar compound
Hydrocarbon derivative
Organonitrogen compound
Organic nitrogen compound
Amine
Organopnictogen compound
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

N-arylpiperazine (CHEBI:7735 )
N-methylpiperazine (CHEBI:7735 )
benzodiazepine (CHEBI:7735 )

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Membrane

Biofluid Locations

Not Available

Tissue Locations

Brain
Liver

Applications

Biological Roles

serotonin uptake inhibitor ?
serotonergic antagonist ?
muscarinic antagonist ?
histamine antagonist ?
dopaminergic antagonist ?
Antidepressant (PMC5217191 )?
antipsychotic agent (PMC3622807 , PMC6197801 )?
second generation antipsychotic (PMC11054165 , PMC5357098 )?

Chemical Roles

Not Available

Organoleptic Effects

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	195°C
Boiling Point	Not Available
Solubility	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.094 g/L	ALOGPS
logP	3.61	ALOGPS
logP	3.39	ChemAxon
logS	-3.5	ALOGPS
pKa (Strongest Acidic)	14.17	ChemAxon
pKa (Strongest Basic)	7.24	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	30.87 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	93.87 m³·mol⁻¹	ChemAxon
Polarizability	35.37 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted GC-MS	Predicted GC-MS Spectrum	splash10-0btd-8090000000-3a1771a0db51f3e9472b	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03dj-0940000000-1103f40c5bb833e12903	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03dj-0940000000-37cb2e8fb99c38b097b8	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-2790000000-bdc5a34b08715b752eef	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0009000000-256a6e976b00468fe839	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0049000000-83ee647255e8d18f2b5c	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-0090000000-81810b42dccae4ee9ab6	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0bt9-0490000000-8994262c6a309d663713	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-01ot-0950000000-ceb0ca01cefbd1da57d7	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0149000000-e74851873e2fbaa6c182	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03dj-0940000000-1103f40c5bb833e12903	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03dj-0940000000-37cb2e8fb99c38b097b8	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0149000000-338b982664cf3019be13	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-2790000000-bdc5a34b08715b752eef	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-01ot-0950000000-fe416acb0e50253f8d17	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0bt9-0490000000-a203abf5daf6a6c6e069	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0049000000-4b7427c44443aab6c7a1	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-0090000000-15b5422aefe3fc372956	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0009000000-d71ce384c72fd5835dac	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-01ot-0950000000-7ba8fbea8f79ae64960d	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0009000000-8a0d8c259665a9adcffe	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-03di-0049000000-68c50295f564feb0c9cf	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0bt9-0490000000-1170974db7ef1a22e129	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-0090000000-eb4ef33b2c2091f8d768	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0002-0940000000-46c2c7bafdd126837e52	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-0390000000-dcd3f6173e3eef45e57f	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0002-0940000000-9457cd78e5131efb9b9e	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0bt9-0490000000-581e7544c51742aaa050	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a4i-0090000000-cee5a94828f155ab2cf6	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0019000000-66bcbe5560546ebe79ae	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0097000000-7386f41b122664655390	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03k9-5980000000-82c2110f56cd7202848e	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0039000000-01aa4f818b0cb4798c0f	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0300-0092000000-cee214399c7899dbbc41	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0a6u-2490000000-dec2f8d13b50769ec96e	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0009000000-3b41bab1710802e24cad	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0019000000-8ef321c8a16784116708	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0a4i-0190000000-1dbcdb8307537def43bb	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0009000000-3c8a25eafdf6ff76538f	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-03di-0009000000-afe5fc2dc1260bb0d78c	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000i-2090000000-3426b323ad1ce5a5592e	Not Available	View Spectrum

Toxicity Profile

Toxicity Values

Toxicity Value	Organism	Dose Descriptor	Route of Exposure	Predicted or Experimental	Toxicity Rating	Reference
265.0 Log mg/kg [150:470]	Rat	LD50	oral	predicted	Not Available	Not Available

Toxicity / Toxin Class

Not Available

Mechanism of Toxicity

Olanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.

Carcinogenicity (IARC Classification)

Not listed by IARC.

Minimum Risk Level

Not Available

Symptoms

Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.

Treatment

In case of acute overdose, establish and maintain an airway and ensure adequate ventilation, which may include intubation. Induction of emesis is not recommended as the possibility of obtundation, seizures, or dystonic reactions of the head and neck following overdose may create a risk for aspiration. Gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. (13)

Health Effects

Health Effect	Relationship	Direction	Description	Reference
fatigue	Associated With?	increase	A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities. (NCI CTCAE)	PMC4163966
weight gain	Associated With?	Not Available	A finding characterized by an increase in overall body weight; for pediatrics, greater than the baseline growth curve. (NCI CTCAE)	PMC2713042 , PMC4163966
schizophrenia	Not Available	Not Available	A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness. (DO)	PMC11505606 , PMC3622807
pneumonia	Associated With?	Not Available	A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. (DO)	PMC7905390
delirium	Not Available	Not Available	A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition. (NCI CTCAE)	PMC7390577 , PMC12985773
thrombosis	Associated With?	increase	A formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.	PMC7905390
agitation	Not Available	Not Available	A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension. (NCI CTCAE)	PMC11859965
antiphospholipid syndrome	Associated With?	Not Available	Not Available	PMC10920025
bipolar disorder	Not Available	Not Available	A mood disorder that involves alternating periods of mania and depression. (DO)	PMC8464795
anxiety disorder	Not Available	Not Available	Not Available	PMC9143978
depressive disorder	Not Available	Not Available	Not Available	PMC9143978
Sudden death	Associated With?	increase	Not Available	PMC7905390
Polyphagia	Associated With?	increase	Not Available	PMC11505606
psychotic disorder	Not Available	Not Available	Not Available	PMC9143978
Central Nervous System Diseases	Not Available	Not Available	Not Available	PMC5574602
Mental Disorders	Not Available	Not Available	Not Available	PMC7466134

Exposure Sources

Source ID	Source	Sector	Reference
CEDs000010	Insecticides?Insecticides are synthetic chemicals designed to control or eliminate insect pests that threaten crops and other agricultural products.	Agriculture & land management	PubChem
CEDs000019	Indoor air?Indoor air can be a significant reservoir for synthetic chemical contaminants, which often originate from various sources within enclosed environments.	Air, dust & atmospheric transport	Not Available
CEDs000233	Brushes?Brushes used in personal care and cosmetics can be a source of synthetic chemical contamination due to the materials and coatings used in their manufacturing.	Personal care & cosmetics	PubChem
CEDs000374	Antipsychotics?Antipsychotics are a class of synthetic chemicals used primarily for the treatment of psychiatric disorders, including schizophrenia and bipolar disorder.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000506	Antennas?Antennas, commonly used in communication technologies, can be a source of synthetic chemical contamination through the materials and coatings used in their construction.	Electrical & Electronic Equipment	PubChem
CEDs000518	Electrically Stimulated Smoking Devices?Electrically stimulated smoking devices, commonly known as e-cigarettes or vape pens, utilize electrical components to heat a liquid solution, often containing nicotine, flavorings, and other additives, to produce an aerosol for inhalation.	Electrical & Electronic Equipment	PubChem
CEDs000519	Electrodes?Electrodes, used in various electrical and electronic applications, can be a source of synthetic chemical contamination due to the materials from which they are constructed and the processes involved in their manufacturing.	Electrical & Electronic Equipment	PubChem
CEDs000530	Radio Transmission Systems?Radio transmission systems utilize a variety of synthetic chemicals in their manufacturing and maintenance processes.	Electrical & Electronic Equipment	PubChem
CEDs000545	Food Preservation?Food preservation often involves the use of synthetic chemicals, such as preservatives, flavor enhancers, and color additives, to extend shelf life and enhance the sensory qualities of food products.	Food, food processing & cookware	PubChem
CEDs000548	Preparation Of Vinegar?Vinegar is produced through the fermentation of ethanol by acetic acid bacteria, resulting in a solution that typically contains 4-8% acetic acid.	Food, food processing & cookware	PubChem
CEDs000549	Preparation Of Wine Or Sparkling Wine?The preparation of wine or sparkling wine involves various stages, including fermentation, aging, and bottling, which can introduce potential sources of synthetic chemical contamination.	Food, food processing & cookware	PubChem
CEDs000556	Cigar Cigarettes?Cigar cigarettes are a source of synthetic chemical contamination due to the combustion of various tobacco blends and additives.	Household cleaning & consumer products	PubChem
CEDs000559	Non Electric Simulated Smoking Devices?Non-electric simulated smoking devices, often designed to mimic the experience of smoking without combustion, can be sources of synthetic chemical contamination due to the materials and chemicals used in their construction and operation.	Household cleaning & consumer products	PubChem
CEDs000560	Other Smoking Requisites?Other smoking requisites, including items such as lighters, matches, and rolling papers, can introduce synthetic chemical contamination through various components and additives.	Household cleaning & consumer products	PubChem
CEDs000561	Perfumes Within Detergents And Soaps?Perfumes within detergents and soaps are synthetic fragrance compounds added to enhance the sensory experience of cleaning products.	Household cleaning & consumer products	PubChem
CEDs000569	Tobacco Smoke Filters?Tobacco smoke filters are designed to reduce the inhalation of harmful substances in cigarette smoke, including tar and other particulate matter.	Household cleaning & consumer products	PubChem
CEDs000579	Manufacture Of Iron Or Steel?The manufacture of iron or steel involves various processes, including smelting, refining, and alloying, which can result in the release of synthetic chemicals and contaminants.	Industrial manufacturing & chemical processing	PubChem
CEDs000580	Manufacture Preparation Of Tobacco Products?The manufacture and preparation of tobacco products involve various processes that can result in the introduction of synthetic chemicals into the environment.	Industrial manufacturing & chemical processing	PubChem
CEDs000596	Acaricides?Acaricides are synthetic chemicals specifically designed to target and control mite populations that can damage crops and plants.	Agriculture & land management	PubChem
CEDs000600	Herbicides And Algicides?Herbicides and algicides are synthetic chemicals primarily used to control unwanted plants and algae in various environments.	Agriculture & land management	PubChem
CEDs000606	Plant Growth Regulators?Plant Growth Regulators (PGRs) are synthetic chemicals designed to influence the growth and development of plants.	Agriculture & land management	PubChem
CEDs000611	Anti Perspirants Or Body Deoderants?Antiperspirants and body deodorants commonly contain synthetic chemicals such as aluminum compounds, parabens, and synthetic fragrances.	Personal care & cosmetics	PubChem
CEDs000615	Eye Makeup Products?Eye makeup products, including mascaras, eyeliners, and eyeshadows, often contain a variety of synthetic chemicals such as pigments, preservatives, and film-forming agents.	Personal care & cosmetics	PubChem
CEDs000632	Apparel?Apparel production often involves the use of various synthetic chemicals, including dyes, finishing agents, and preservatives.	Textiles, leather & furnishings	PubChem
CEDs000642	Footwear?Footwear production often involves the use of various synthetic chemicals, such as adhesives, dyes, and treatments, which can contribute to environmental contamination.	Textiles, leather & furnishings	PubChem
CEDs000650	Purses Luggage Hand Bags?Purses, luggage, and handbags are often manufactured using synthetic materials such as polyvinyl chloride (PVC), polyurethane, and various types of nylon.	Textiles, leather & furnishings	PubChem
CEDs000671	Airplanes And Helicopters?Airplanes and helicopters are significant sources of synthetic chemical contamination primarily through the use of aviation fuels, lubricants, and de-icing agents.	Aviation & Aerospace	PubChem
CEDs000685	Ceramics?Ceramics can be a source of synthetic chemical contamination through various additives and processing agents used in their production.	Building & Construction	PubChem
CEDs000688	Glass Coatings?Glass coatings are synthetic chemical formulations applied to glass surfaces to enhance properties such as durability, UV resistance, and aesthetic appeal.	Building & Construction	PubChem
CEDs000696	Nanotechnology?Nanotechnology involves the manipulation of materials at the molecular or atomic level, typically within the range of 1 to 100 nanometers.	Industrial manufacturing & chemical processing	PubChem
CEDs000698	Jewellery?Jewellery production often involves the use of various synthetic chemicals during the extraction and processing of metals.	Mining & metal processing	PubChem
CEDs000705	Bookbinding?Bookbinding involves the use of various synthetic chemicals, including adhesives, inks, and coatings, which can contribute to environmental contamination.	Paper, pulp & fiber products	PubChem
CEDs000727	Printing Machines Or Presses?Printing machines or presses commonly utilize synthetic chemicals such as inks, solvents, and cleaning agents.	Paper, pulp & fiber products	PubChem
CEDs000735	Explosives?Explosives are chemical compounds or mixtures designed to undergo rapid decomposition, releasing energy in the form of gas and heat.	Defense & military infrastructure	PubChem
CEDs000739	Inks?Inks are complex mixtures composed of pigments or dyes, solvents, resins, and additives used primarily for printing and writing applications.	Paper, pulp & fiber products	PubChem
CEDs000740	Paper?Paper production involves the processing of wood fibers and the use of various chemicals, which can lead to synthetic chemical contamination.	Paper, pulp & fiber products	PubChem
CEDs000741	Pigment Pastes?Pigment pastes are concentrated dispersions of pigments used to impart color and properties to materials.	Paper, pulp & fiber products	PubChem
CEDs000744	Water, Wastewater, & Sewage Treatment?Water, wastewater, and sewage treatment processes are critical for managing and mitigating pollutants in water systems.	Wastewater, sanitation & biosolids	PubChem
CEDs01148	Milk	Food, food processing & cookware	PMC13318911
CEDs02265	River Water	Aquatic systems & sediments	PMC5306312
CEDs03009	Waste Water	Wastewater, sanitation & biosolids	PMC10052509

Pathways

7 pathwaysPathway Source: PathBank

Olanzapine Serotonin Antagonist Action Pathway

Olanzapine Dopamine Antagonist Action Pathway

Olanzapine Drug Metabolism Action Pathway

Olanzapine H1 Antihistamine Neurological Sleep Action Pathway

Olanzapine H1 Antihistamine Smooth Muscle Relaxation Action Pathway

Olanzapine H1-Antihistamine Blood Vessel Constriction Action Pathway

Olanzapine H1-Antihistamine Immune Response Action Pathway

Targets

Structure	Protein	UniProt ID	Organism	Relationship	Details
Click to view 3D structure	Cytochrome P450 3A43	Q9HB55	Humans	Known	Not Available
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Predicted (SEA)	Prediction Confidence Score 0.663 Applicability Domain 1.0 Statistical Significance 0.0011 Supporting Reference Compounds 1103 E-value 8.48557
Click to view 3D structure	D(2) dopamine receptor	P61169	Rat	Predicted (SEA)	Prediction Confidence Score 0.639 Applicability Domain 1.0 Statistical Significance 0.001 Supporting Reference Compounds 528 E-value 7.94062
Click to view 3D structure	D(1A) dopamine receptor	P18901	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.639 Applicability Domain 1.0 Statistical Significance 3.60e-04 Supporting Reference Compounds 206 E-value 2.80257
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P14842	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.621 Applicability Domain 1.0 Statistical Significance 4.00e-04 Supporting Reference Compounds 380 E-value 3.11397
Click to view 3D structure	Muscarinic acetylcholine receptor M1	P11229	Humans	Predicted (SEA)	Prediction Confidence Score 0.621 Applicability Domain 1.0 Statistical Significance 3.40e-04 Supporting Reference Compounds 385 E-value 2.64687
Click to view 3D structure	Cytochrome P450 1A2	P05177	Humans	Known	Not Available
Click to view 3D structure	D(1A) dopamine receptor	P21728	Humans	Predicted (SEA)	Prediction Confidence Score 0.612 Applicability Domain 1.0 Statistical Significance 7.00e-04 Supporting Reference Compounds 425 E-value 5.44945
Click to view 3D structure	D(4) dopamine receptor	P21917	Humans	Predicted (SEA)	Prediction Confidence Score 0.596 Applicability Domain 1.0 Statistical Significance 0.0011 Supporting Reference Compounds 524 E-value 8.25202
Click to view 3D structure	Histamine H1 receptor	P35367	Humans	Predicted (SEA)	Prediction Confidence Score 0.593 Applicability Domain 1.0 Statistical Significance 5.80e-04 Supporting Reference Compounds 507 E-value 4.51525
Click to view 3D structure	Histamine H1 receptor	P31390	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.589 Applicability Domain 1.0 Statistical Significance 1.00e-04 Supporting Reference Compounds 63 E-value 0.778492
Click to view 3D structure	UDP-glucuronosyltransferase 1A3	P35503	Humans	Known	Not Available
Click to view 3D structure	D(3) dopamine receptor	P35462	Humans	Predicted (SEA)	Prediction Confidence Score 0.576 Applicability Domain 1.0 Statistical Significance 0.0022 Supporting Reference Compounds 861 E-value 16.9711
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Predicted (SEA)	Prediction Confidence Score 0.533 Applicability Domain 1.0 Statistical Significance 0.0032 Supporting Reference Compounds 955 E-value 24.8339
Click to view 3D structure	5-hydroxytryptamine receptor 6	P50406	Humans	Predicted (SEA)	Prediction Confidence Score 0.523 Applicability Domain 1.0 Statistical Significance 0.0013 Supporting Reference Compounds 536 E-value 10.5096
Click to view 3D structure	Muscarinic acetylcholine receptor M5	P08912	Humans	Predicted (SEA)	Prediction Confidence Score 0.514 Applicability Domain 1.0 Statistical Significance 3.30e-04 Supporting Reference Compounds 266 E-value 2.56902
Click to view 3D structure	Muscarinic acetylcholine receptor M2	P08172	Humans	Predicted (SEA)	Prediction Confidence Score 0.514 Applicability Domain 1.0 Statistical Significance 4.90e-04 Supporting Reference Compounds 373 E-value 3.81461
Click to view 3D structure	Muscarinic acetylcholine receptor M3	P20309	Humans	Predicted (SEA)	Prediction Confidence Score 0.514 Applicability Domain 1.0 Statistical Significance 6.30e-04 Supporting Reference Compounds 310 E-value 4.9045
Click to view 3D structure	Muscarinic acetylcholine receptor M4	P08173	Humans	Predicted (SEA)	Prediction Confidence Score 0.514 Applicability Domain 1.0 Statistical Significance 5.30e-04 Supporting Reference Compounds 297 E-value 4.12601
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P08909	Rat	Predicted (SEA)	Prediction Confidence Score 0.513 Applicability Domain 0.574 Statistical Significance 9.70e-04 Supporting Reference Compounds 185 E-value 7.55137
Click to view 3D structure	Alpha-2A adrenergic receptor	P08913	Humans	Predicted (SEA)	Prediction Confidence Score 0.505 Applicability Domain 1.0 Statistical Significance 0.0014 Supporting Reference Compounds 487 E-value 10.6653
Click to view 3D structure	Voltage-gated inwardly rectifying potassium channel KCNH2	Q12809	Humans	Predicted (SEA)	Prediction Confidence Score 0.502 Applicability Domain 1.0 Statistical Significance 0.006 Supporting Reference Compounds 1498 E-value 46.8652
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Predicted (SEA)	Prediction Confidence Score 0.496 Applicability Domain 1.0 Statistical Significance 0.0065 Supporting Reference Compounds 953 E-value 50.2906
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Predicted (SEA)	Prediction Confidence Score 0.495 Applicability Domain 1.0 Statistical Significance 0.0032 Supporting Reference Compounds 565 E-value 24.9118
Click to view 3D structure	Alpha-2C adrenergic receptor	P18825	Humans	Predicted (SEA)	Prediction Confidence Score 0.494 Applicability Domain 1.0 Statistical Significance 0.0011 Supporting Reference Compounds 386 E-value 8.48557
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P28335	Humans	Predicted (SEA)	Prediction Confidence Score 0.491 Applicability Domain 1.0 Statistical Significance 0.004 Supporting Reference Compounds 823 E-value 30.8283
Click to view 3D structure	Alpha-2B adrenergic receptor	P18089	Humans	Predicted (SEA)	Prediction Confidence Score 0.49 Applicability Domain 1.0 Statistical Significance 9.60e-04 Supporting Reference Compounds 340 E-value 7.47353
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Predicted (SEA)	Prediction Confidence Score 0.49 Applicability Domain 1.0 Statistical Significance 0.0026 Supporting Reference Compounds 686 E-value 20.1629
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P28335	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Histamine H1 receptor	P35367	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	D(3) dopamine receptor	P35462	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	D(4) dopamine receptor	P21917	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Voltage-gated inwardly rectifying potassium channel KCNH2	Q12809	Humans	Known	Not Available
Click to view 3D structure	Muscarinic acetylcholine receptor M1	P11229	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	5-hydroxytryptamine receptor 6	P50406	Humans	Known	Not Available
Click to view 3D structure	D(1A) dopamine receptor	P21728	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Known	Not Available
Click to view 3D structure	Alpha-1A adrenergic receptor	P35348	Humans	Known	Not Available
Click to view 3D structure	Alpha-2A adrenergic receptor	P08913	Humans	Known	Not Available
Click to view 3D structure	Alpha-2C adrenergic receptor	P18825	Humans	Known	Not Available
Click to view 3D structure	D(1B) dopamine receptor	P21918	Humans	Known	Not Available
Click to view 3D structure	Muscarinic acetylcholine receptor M2	P08172	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Muscarinic acetylcholine receptor M3	P20309	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Muscarinic acetylcholine receptor M4	P08173	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Muscarinic acetylcholine receptor M5	P08912	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28222	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1D	P28221	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1E	P28566	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 3A	P46098	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 5A	P47898	Humans	Known	Not Available
Click to view 3D structure	Alpha-1B adrenergic receptor	P35368	Humans	Known	Olanzapine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Olanzapine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT₂ receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Olanzapine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with olanzapine.
Click to view 3D structure	Alpha-2B adrenergic receptor	P18089	Humans	Known	Not Available
Click to view 3D structure	Histamine H2 receptor	P25021	Humans	Known	Not Available
Click to view 3D structure	Histamine H4 receptor	Q9H3N8	Humans	Known	Not Available
Click to view 3D structure	Sodium-dependent serotonin transporter	P31645	Humans	Known	Not Available

Concentrations

Not Available

External Links

DrugBank ID

DB00334

HMDB ID

HMDB0005012

FooDB ID

FDB023585

Phenol Explorer ID

Not Available

KNApSAcK ID

Not Available

BiGG ID

Not Available

BioCyc ID

Not Available

METLIN ID

Not Available

PDB ID

Not Available

Wikipedia Link

Chemspider ID

ChEBI ID

PubChem Compound ID

Kegg Compound ID

YMDB ID

Not Available

ECMDB ID

Not Available

References

Synthesis Reference

Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, “Intermediates and process for preparing olanzapine.” U.S. Patent US6020487, issued September, 1996.

MSDS

Link

General References

Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [PubMed: 18048412]
de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. [PubMed: 15322727]
Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. [PubMed: 16139813]
Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. [PubMed: 16415705]
Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. [PubMed: 12752037]
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. [PubMed: 12648731]
Horak EL, Jenkins AJ: Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J Forensic Sci. 2005 May;50(3):679-81. [PubMed: 15932107]
Cerdan LF, Guevara MA, Sanz A, Amezcua C, Ramos-Loyo J: Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment. Int J Psychophysiol. 2005 Jun;56(3):237-47. [PubMed: 15866327]
Yamada K, Isotani T, Irisawa S, Yoshimura M, Tajika A, Yagyu T, Saito A, Kinoshita T: EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers. Brain Topogr. 2004 Summer;16(4):281-5. [PubMed: 15379228]
Mortimer A, Martin S, Loo H, Peuskens J: A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004 Mar;19(2):63-9. [PubMed: 15076013]
Merrick TC, Felo JA, Jenkins AJ: Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol. 2001 Sep;22(3):270-4. [PubMed: 11563738]
Drugs.com - http://www.drugs.com/cons/Olanzapine.html
RxList: The Internet Drug Index (2009). - http://www.rxlist.com/

Olanzapine (CED0001774)

Structure for CHEM002173: Olanzapine

Structure